Bhagat v. PTO

Court of Appeals for the Federal Circuit·Decided April 3, 2024·No. 23-1545·Unpublished

Opinion

NOTE: This disposition is nonprecedential.

United States Court of Appeals for the Federal Circuit

URVASHI BHAGAT, Plaintiff-Appellant

v.

UNITED STATES PATENT AND TRADEMARK OFFICE, KATHERINE K. VIDAL, IN HER OFFICIAL CAPACITY AS UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE, UNITED STATES,

Defendants-Appellees

2023-1545

Appeal from the United States District Court for the Eastern District of Virginia in No. 1:20-cv-01515-CMH- IDD, Senior Judge Claude M. Hilton.

Decided: April 3, 2024

URVASHI BHAGAT, Palo Alto, CA, pro se.

MAUREEN DONOVAN QUELER, Office of the Solicitor, United States Patent and Trademark Office, Alexandria, 2 BHAGAT v. PTO

VA, for defendants-appellees. Also represented by OMAR FAROOQ AMIN, MARY L. KELLY, THOMAS W. KRAUSE, FARHEENA YASMEEN RASHEED; JESSICA D. ABER, MATTHEW JAMES MEZGER, Office of the United States Attorney for the Eastern District of Virginia, United States Department of Justice, Alexandria, VA.

Before PROST, CLEVENGER, and CUNNINGHAM, Circuit Judges.

PER CURIAM.

Urvashi Bhagat (“Bhagat”) appeals several orders from the United States District Court for the Eastern District of Virginia: requiring Bhagat to file paper motions to the court, rejecting her requests for discovery enlargement and rescheduling of the pretrial conference, denying her request to file a second amended complaint, denying her request to exclude an expert, granting defendant United States Patent and Trademark Office’s (“PTO”) partial motion to dismiss Bhagat’s causes of action unrelated to patentability , denying her request to strike the PTO’s motion for summary judgment and granting that motion finding that Bhagat’s patent claims are ineligible under 35 U.S.C. §§ 101 and 103. Bhagat also asserts various due process violations against the district court. We affirm.

BACKGROUND

A. The Patent Application Bhagat is the inventor of the United States Patent Application No. 13/877,847 (the “Application”). The Application claims are directed to nutritional formulations containing omega-6 fatty acids and antioxidants, which the Application describes as contained “in any orally acceptable form, including, capsules, tablets, liquid formulations, or whole foods” and administered orally. The Application claims a “packaged product” where “the intermixture of

BHAGAT v. PTO 3

omega-6 fatty acid(s) and antioxidant(s) is not any single specific variety of a vegetable, a fruit, a nut, or a seed,” and the dosage ranges “from 1 to 40g of omega-6 fatty acids and from 25mg to 10g of antioxidants . . . wherein the antioxidants comprise one or more polyphenols in the dosage of greater than 5mg.” App. Br. to PTO at 46, claim 82. The Application also claims the product in a “kit” that includes a range of two to twenty different nutritional formulations, “which collectively provide an amount of nutrients from 0.0001 to 100 g/kg body weight . . . 40-80% of individual’s daily calories . . . 10-50% calories from protein, 15-50% calories from lipids, and 35-85% calories from carbohydrates; and/or . . . deliver at least 50% of daily micronutrients for the individual” and/or is made up of “at least one of: vegetable or vegetable juice packs, fruit or fruit juice packs, dry grain packs, cereal packs, legume, grain, nuts, or seed packs, meat or seafood packs, or herbs, lipids, meals, snack, side dish, salad, desserts, milks, powder, puree, or yogurt packs.” App. Br. to PTO at 23–4, claim 95.

The Application also contains method claims, wherein claim 88 sets out steps for “administering the dosage to an individual, wherein the individual belongs to a diet cohort” based on factors like “gender, age, genetic profile, family history, climactic temperature, or medical condition,” claim 97 describes a method for treating “a medical condition or disease in the individual” and claim 116 recites a method for treating a variety of conditions such as aging, mental disorders, diabetes, autoimmune and infectious diseases. App. Br. to PTO at 21, 24, 31–32, claims 88, 97, and 116. None of the method claims, however, “include tailoring the nutrient dosages in the product to the diet cohort or restricting the total daily intake of any of the claimed nutrients .” J.A. 21.

The Application additionally includes a withdrawn claim directed to a computer system to implement the method claims and to output nutritional plans for individuals based on dietary preferences and guidelines “wherein 4 BHAGAT v. PTO

the nutrition program comprises a listing of formulations, optionally comprising food items, wherein from 1 to 40g of omega-6 fatty acids and from 5mg to 10g of antioxidants comprising at least 5mg of one or more polyphenols are included in the program for daily consumption by the individual .” App. Br. to PTO at 29–30, claim 112.

B. Procedural History 1. PTO Proceedings

Bhagat filed the Application with the PTO in 2013. The PTO examiner rejected all pending claims of the Application for obviousness and rejected claims 82 and 99 for failing to comply with the written description requirement, claims 82, 87, 91–93, 96, 97, 99, 102, 109, 110, and 113–120 for indefiniteness, and claims 88, 89, 95, 103, and 107–110 for improper dependency.

Bhagat appealed to the Patent Trial and Appeal Board (“Board”), which reversed the rejection for written description and affirmed the rejection for obviousness on the merits . 1 The Board affirmed the obviousness rejection because the Application claims were “obvious in light of numerous past expert studies and disclosures,” particularly Claudia R. Morris’s U.S. Published Patent Application Number 2008/0213239 (“Morris”). Bhagat v. U.S. Pat. & Trademark Off., No. 1:20-cv-1515, 2023 WL 2721003, at *2 (E.D. Va. Mar. 30, 2023) (“Summary Judgment Opinion”).

The Board explained that Morris addresses the treatment of various conditions, like cardiovascular disease, by disclosing nutritional formulations comprising omega-6

1 The Board summarily affirmed the rejections based on indefiniteness and improper dependency because Bhagat failed to include in her Appeal Brief any substantive arguments on the merits that the rejections on those grounds should be reversed. J.A. 5980, 6480.

BHAGAT v. PTO 5

fatty acids and Vitamin E in dosages and amounts that overlap with those in the Application claims. Id. at *2 (“Morris shows that the formulations comprise from about 50 mg to about 500 mg omega-6 fatty acids that may be administered once, twice, or three times daily, which would equal a dosage ranging from 50 mg to 1,500 mg of omega-6 fatty acids a day.”). The Board also found that Morris disclosed packaged formulations of omega-6 fatty acids, Vitamin E, and polyphenols, as well as dosages of omega-6 and Vitamin E in the ranges claimed in the Application claims and disclosed that “dosages are a result-effective variable and may be optimized for an individual,” rendering the Application ’s claimed dosages obvious. Id. Factors discussed in Morris as impacting the preparation of formulations include age, weight, and genetic makeup, which overlap with the diet cohort factors in the Application. Id. at *2. The Board found that Morris disclosed most of what the claimed invention covered, and that the only difference— that the Application disclosed using nutrients from different sources—was rendered obvious from other expert disclosures teaching the mixtures of different nutrient sources. Id. at *2 (“The only difference the Board found between Morris and [the Application’s] claimed formulation was an explicit disclosure of using nutrients from different sources . . . . [which] would have been obvious in light of another expert’s teachings of oil blends from different sources.”).

Free access — add to your briefcase to read the full text and ask questions with AI

Bhagat v. PTO, (Fed. Cir. 2024).

Bhagat v. PTO (Bhagat v. PTO) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

United States v. Testan
424 U.S. 392 (Supreme Court, 1976)
United States v. Mitchell
445 U.S. 535 (Supreme Court, 1980)
Lehman v. Nakshian
453 U.S. 156 (Supreme Court, 1981)
Cleveland Board of Education v. Loudermill
470 U.S. 532 (Supreme Court, 1985)
Aetna Life Insurance v. Lavoie
475 U.S. 813 (Supreme Court, 1986)
Lujan v. National Wildlife Federation
497 U.S. 871 (Supreme Court, 1990)
Daubert v. Merrell Dow Pharmaceuticals, Inc.
509 U.S. 579 (Supreme Court, 1993)
Liteky v. United States
510 U.S. 540 (Supreme Court, 1994)
Eastern Enterprises v. Apfel
524 U.S. 498 (Supreme Court, 1998)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Symbionics Inc. v. Ortlieb
432 F. App'x 216 (Fourth Circuit, 2011)
Harrods Limited v. Sixty Internet Domain Names
302 F.3d 214 (Fourth Circuit, 2002)